Image

    Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer

    December 2003 in “ Clinical breast cancer
    Joyce O’Shaughnessy
    Studysummary The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on clinical-breast-cancer.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Prevention and Treatment of Adverse Effects Related to Chemotherapy for Recurrent Ovarian Cancer Seminars in oncology nursing · 2003
    2. Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy Cancer investigation · 2001
    3. Correlation of Toxicity With Pharmacokinetics of Pegylated Liposomal Doxorubicin (Doxil) in Metastatic Breast Carcinoma Cancer · 2000